Table 2 |
|||
|
Timing and dose at treatment discontinuation |
|||
|
Dose of escitalopram |
Week of last completed visit |
Number of patients discontinued |
|
|
|
|||
|
Due to an AEa |
Not due to an AEa |
||
|
|
|||
|
10 mg |
Week 0 (baseline) |
6 |
0 |
|
Week 8 |
1 |
0 |
|
|
20 mg |
Week 4 |
1 |
0 |
|
Week 16 |
1 |
0 |
|
|
30 mg |
Week 8 |
1 |
0 |
|
35 mg |
Week 8 |
0 |
2 (1 - ineligible to continue, 1 - lack of efficacy) |
|
40 mg |
Week 24 |
1 |
0 |
|
45 mg |
Week 24 |
1 |
1 (lack of efficacy) |
|
50 mg |
Week 16 |
1 |
0 |
|
Week 20 |
0 |
1 (lost to follow up) |
|
|
Week 24 |
0 |
1 (lack of efficacy) |
|
|
|
|||
|
a AE: adverse event. The reason for withdrawal was taken from the End of Study Case Report Form (CRF) page. This stated that a patient withdrew due to an AE, although this was not recorded as a withdrawal as a result of an AE on the AE CRF page |
|||
|
Wade et al. BMC Psychiatry 2011 11:42 doi:10.1186/1471-244X-11-42 |
|||
